Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1989 1
1991 1
1992 2
1993 2
1994 1
1995 1
1996 1
1997 1
1998 1
2000 1
2001 2
2002 1
2004 1
2005 1
2006 2
2007 4
2008 1
2009 2
2010 2
2011 3
2012 4
2013 8
2014 14
2015 8
2016 9
2017 7
2018 8
2019 15
2020 25
2021 36
2022 37
2023 45
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.
Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Leung AKC, et al. Curr Pediatr Rev. 2021;17(4):273-287. doi: 10.2174/1573396317666210426105045. Curr Pediatr Rev. 2021. PMID: 33902423 Review.
In the absence of muscle biopsy, a definite diagnosis of idiopathic inflammatory myopathy can be made if the total score is 7.5. Patients whose age at onset of symptoms is less than 18 years and who meet the above criteria for idiopathic infl …
In the absence of muscle biopsy, a definite diagnosis of idiopathic inflammatory myopathy can be made if the total s …
Antisynthetase syndrome - much more than just a myopathy.
Opinc AH, Makowska JS. Opinc AH, et al. Semin Arthritis Rheum. 2021 Feb;51(1):72-83. doi: 10.1016/j.semarthrit.2020.09.020. Epub 2020 Dec 22. Semin Arthritis Rheum. 2021. PMID: 33360231 Review.
The prevalence of symptoms vary significantly depending on the study with muscular, articular and pulmonary involvement being the most frequently observed. Although classified as subtype of idiopathic inflammatory myopathies, myositis may not necessarily be the prominent m …
The prevalence of symptoms vary significantly depending on the study with muscular, articular and pulmonary involvement being the most frequ …
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G, Antonini G, Garibaldi M. Merlonghi G, et al. Autoimmun Rev. 2022 Feb;21(2):102993. doi: 10.1016/j.autrev.2021.102993. Epub 2021 Nov 16. Autoimmun Rev. 2022. PMID: 34798316 Review.
Low fibre size variability with overexpression of both MHC-I and II, associated with C5b-9 deposition, could could be observed in CIM, while increased connective tissue should lead to consider MD, or TM in absence of C5b-9 deposition. ...
Low fibre size variability with overexpression of both MHC-I and II, associated with C5b-9 deposition, could could be observed in CIM …
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. Satoh M, et al. Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19. doi: 10.1007/s12016-015-8510-y. Clin Rev Allergy Immunol. 2017. PMID: 26424665 Free PMC article. Review.
Autoantibodies specific for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)) are clinically useful biomarkers to help the diagnosis of polymyositis/dermatomyositis (PM/DM). Many of these are also associated with a unique clinical sub …
Autoantibodies specific for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)) are clinically u …
Idiopathic inflammatory myositis.
Tieu J, Lundberg IE, Limaye V. Tieu J, et al. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):149-68. doi: 10.1016/j.berh.2016.04.007. Epub 2016 May 26. Best Pract Res Clin Rheumatol. 2016. PMID: 27421222 Review.
Knowledge on idiopathic inflammatory myopathy (IIM) has evolved with the identification of myositis-associated and myositis-specific antibodies, development of histopathological classification and the recognition of how these correlate with clinical phenotype …
Knowledge on idiopathic inflammatory myopathy (IIM) has evolved with the identification of myositis-associated and myos …
Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y, Ye L, Chen F, Shen Y, Lu X, Wang G, Shu X. Zuo Y, et al. Front Immunol. 2022 Mar 7;13:845988. doi: 10.3389/fimmu.2022.845988. eCollection 2022. Front Immunol. 2022. PMID: 35320936 Free PMC article.
OBJECTIVE: The aim of this study was to construct multivariable prediction risk factors for rapid progressive ILD (RP-ILD) in anti-MDA5 positive DM (MDA5(+)DM) and ASS. METHODS: 333 idiopathic inflammatory myopathy (IIM) associated ILD patients were st …
OBJECTIVE: The aim of this study was to construct multivariable prediction risk factors for rapid progressive ILD (RP-ILD) in anti-MD …
Current Biomarker Strategies in Autoimmune Neuromuscular Diseases.
Oeztuerk M, Henes A, Schroeter CB, Nelke C, Quint P, Theissen L, Meuth SG, Ruck T. Oeztuerk M, et al. Cells. 2023 Oct 15;12(20):2456. doi: 10.3390/cells12202456. Cells. 2023. PMID: 37887300 Free PMC article. Review.
The identification of specific biomarkers has the potential to provide valuable insights into disease pathogenesis, aid in accurate diagnosis, predict disease course, and monitor treatment efficacy. However, the rarity and heterogeneity of these disorders pose significant …
The identification of specific biomarkers has the potential to provide valuable insights into disease pathogenesis, aid in accurate diagnosi …
Juvenile dermatomyositis: Latest advances.
Wu Q, Wedderburn LR, McCann LJ. Wu Q, et al. Best Pract Res Clin Rheumatol. 2017 Aug;31(4):535-557. doi: 10.1016/j.berh.2017.12.003. Epub 2018 Jan 10. Best Pract Res Clin Rheumatol. 2017. PMID: 29773272 Review.
Genotype, autoantibodies, muscle histology and early clinical features may predict prognosis and guide personalised treatment. While corticosteroids and disease-modifying anti-rheumatic drugs improve outcomes, there remain children who experience refractory disease. ...
Genotype, autoantibodies, muscle histology and early clinical features may predict prognosis and guide personalised treatment. While …
Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease.
Zekić T. Zekić T. Rheumatol Int. 2023 Jun;43(6):1015-1021. doi: 10.1007/s00296-023-05302-9. Epub 2023 Mar 16. Rheumatol Int. 2023. PMID: 36928934 Review.
Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy (IIM). In comparison to interstitial lung disease (ILD) in polymyositis and dermatomyositis (PM/DM), ILD in ASS is more frequent, has a more aggressive phenotype, a greater involvement of t …
Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy (IIM). In comparison to interstitial lung disease …
Belimumab treatment of adult idiopathic inflammatory myopathy.
Marder G, Quach T, Chadha P, Nandkumar P, Tsang J, Levine T, Schiopu E, Furie R, Davidson A, Narain S. Marder G, et al. Rheumatology (Oxford). 2024 Mar 1;63(3):742-750. doi: 10.1093/rheumatology/kead281. Rheumatology (Oxford). 2024. PMID: 37326854 Clinical Trial.
OBJECTIVE: To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). METHODS: We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV belimumab 10 mg/kg …
OBJECTIVE: To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopat …
231 results